Agilent Technologies and Seoul National University hospital collaborate on biomarker research
Goals include development, verification of biomarkers for use in drug development
SANTA CLARA, Calif., and SEOUL, Korea -- Agilent Technologies Inc. (NYSE: A) and Seoul National University Hospital, one of Korea's top medical centers, today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
'There are gaps in the medical industry that hamper the quality of care we can provide to patients,' said Prof. Byung-Hee Oh, president and CEO, Seoul National University Hospital. 'One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases.'
'Our hospital is pleased to collaborate with Agilent, the premier test and measurement company, to help us stretch the horizons of medical research in order to improve the lives of people in Korea and around the world,' he said.
Under the agreement, the hospital's Department of Laboratory Medicine will use the Agilent 6460 Triple Quadrupole LC/MS system as well as Agilent's support services and application expertise. The hospital is committed to creating and maintaining an optimal environment for new biomarkers to be identified and tested rigorously by highly sensitive yet robust instruments.
'We are privileged to partner with Seoul National University Hospital, which has a strong tradition of innovation and quality care for customers,' said Agilent's Rod Minett, general manager, Life Sciences, South Korea and the South Asia-Pacific region. 'Through this collaboration, we hope to establish more effective and varied verifications system for the medical and life sciences industries.'
About Seoul National University Hospital
Seoul National University Hospital has been looking after public health over the past 100 years, leading the development of medicine in Korea. It was established in 1885 as Korea's first national hospital under the name of Kwang Hye Won. It became the affiliate hospital for Seoul National University's College of Medicine and College of Dentistry before being recognized as a special corporate body under the name of Seoul National University Hospital. Today, the hospital is comprised of the Main Hospital, the Children's Hospital, the Caner Hospital, the Dental Hospital, and the Clinical Research Institute. For more information, please visit www.snuh.org/english.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had net revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
Related news
-
Creative Proteomics Lipidomics Announces Exosomes Lipidomics Service to Identify Lipid-based Biomarkers
Lipidomics, a division of Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The product manager has recently announced the fully-developed exosomes lipidomics service to help identify lipid-based biomarkers and unravel its monitoring function in diseases. Exosomes are considered to be a new and effective intercellular communication carrier. Adjacent cells or distant cells...
-
Creative Proteomics Announces the Launch of Its New Metabolomics Division
Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and dedication, Creative Proteomics is very excited to announce the launch of the newly-developed metabolomics division...
-
Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation in providing contract services specialized for metabolomics. Recently, the company announced the untargeted metabolomics service, which is a powerful tool for large-scale early phase diagnosis and...
-
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an oral poster presentation entitled, Predicted Metabolites from Multiple Microbiome Sequencing Datasets Modulate Autism...
-
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. Under the terms of the agreement, Second Genome will utilize its proprietary sg-4sight...
Customer comments
No comments were found for Agilent Technologies and Seoul National University hospital collaborate on biomarker research. Be the first to comment!